NON-HODGKIN LYMPHOMA

This study provides access to unlicensed, frozen cord blood units for transplant in children and adults with blood cancers and other serious blood disorders. Researchers aim to track how well patients' immune systems recover after transplant and monitor survival rates and complic…

This study is testing a new oral medication called AS-1763 (docirbrutinib) for adults with certain blood cancers that have returned or stopped responding to at least two prior treatments. The main goals are to find a safe and effective dose and to see how well the drug works agai…

This study is testing a new oral medication called BGB-16673 for people with various B-cell blood cancers that have come back or stopped responding to prior therapies. The main goals are to find a safe and effective dose and to see how well the drug shrinks tumors and controls th…

This study is testing whether taking two oral medications, pirtobrutinib and venetoclax, together can help control mantle cell lymphoma that has come back or stopped responding to other treatments. It will enroll about 30 adults whose cancer has relapsed or is resistant to therap…

This early-stage study is testing a new oral medication called SGR-1505 in adults with advanced B-cell cancers that have returned or stopped responding to previous treatments. The main goal is to find the highest safe dose and understand how the drug affects the body. Researchers…

This early-stage trial is testing an experimental drug called CCS1477 (inobrodib) in people with advanced blood cancers that have returned or stopped responding to standard treatments. The study will give the drug alone and in combination to about 250 patients to check if it is s…

This study is testing whether adding the drug ibrutinib to standard chemotherapy can better control a rare and aggressive cancer called primary central nervous system lymphoma (PCNSL). It is for adults newly diagnosed with this brain cancer who are not eligible for a stem cell tr…

This study is testing whether combining a new drug called epcoritamab with other cancer medications can help control aggressive Non-Hodgkin Lymphoma. Researchers will enroll 496 adults whose cancer has returned after previous treatments or who are newly diagnosed. The main goal i…

This early-stage study is testing a new treatment for people whose lymphoma or leukemia has returned or hasn't responded to standard therapies. Doctors take a patient's own immune cells (T-cells), genetically modify them in a lab to better recognize and attack cancer cells, and t…

This is an early-stage study testing a new type of CAR-T cell therapy called PIC1 injection for adults with B-cell non-Hodgkin lymphoma that has come back or not responded to standard treatments. The main goal is to check the safety of the treatment and see if it can help control…

This early-stage trial is testing the safety and best dose of a new type of CAR-T cell therapy. The therapy uses a patient's own modified immune cells to target two proteins (CD19 and CD22) on lymphoma cells. It is for adolescents and adults whose B-cell non-Hodgkin lymphoma has …

This study is testing whether a new formulation of the chemotherapy drug carmustine causes fewer side effects than the standard version when used as part of the high-dose chemotherapy given before a stem cell transplant. The trial will enroll about 49 adults with Hodgkin or non-H…

This study is testing a modified, gentler two-step method to prepare patients for a stem cell transplant. The goal is to reduce the risk of death from the transplant procedure itself for people with various blood cancers and disorders. Researchers are comparing two lower-intensit…

This early-stage study is testing whether it's safe to give patients a second dose of CAR-T cell therapy if their aggressive lymphoma returns after the first treatment. Researchers will enroll about 20 adults whose cancer came back despite receiving standard CAR-T therapy. The ma…

This study is testing a specific type of stem cell transplant using donated umbilical cord blood to treat patients with serious blood cancers and disorders. The procedure involves high-dose chemotherapy and radiation to wipe out the patient's diseased bone marrow before infusing …

This study is testing the safety and effectiveness of a combination of five targeted drugs (called ViPOR) for adults whose B-cell lymphoma has come back or not improved after prior treatment. The goal is to see if this drug mix can control the cancer. Participants will receive th…

This early-stage study is testing whether adding the drug pomalidomide to standard chemotherapy (with or without rituximab) is safe and tolerable for adults with HIV and aggressive B-cell lymphomas. The main goal is to find the highest dose that doesn't cause severe side effects.…

This is the first human study to test the safety and early effects of an experimental cell therapy called KSV01. It is for adults with a specific type of aggressive blood cancer (B-cell non-Hodgkin lymphoma) that has come back or hasn't responded to other treatments. The main goa…

This is the first study in people to test the safety of an experimental drug called AXT-1003. It is for adults with advanced solid tumors or non-Hodgkin lymphoma that have not responded to standard treatments. The main goal is to find a safe dose and see how the body processes th…

This study is testing a new type of cell therapy for people with advanced solid tumors that have stopped responding to standard treatments. Doctors will analyze a patient's tumor to select a specific target, then infuse specially engineered immune cells (CAR-NK cells) from a heal…

This early-phase trial is testing a combination treatment for adults with B-cell lymphomas that have come back or stopped responding to standard therapies. The approach involves giving patients a daily oral drug (pirtobrutinib) before and after an infusion of their own geneticall…

This early-stage study is testing a new drug called CHO-H01, both by itself and combined with an existing drug (lenalidomide), for people with non-Hodgkin lymphoma that has returned or not responded to other treatments. The first part checks the safety and best dose of CHO-H01. T…

This is the first study in people to test a new oral drug called SB-4826 for advanced solid tumors and non-Hodgkin lymphoma. The main goals are to find the highest safe dose and see how the body processes the drug. For lymphoma patients, the drug will also be tested in combinatio…

This early-stage study is testing a new version of a cancer treatment called CAR-T cell therapy for people whose lymphomas have returned or not responded to standard treatments. Researchers are using pre-made immune cells from healthy donors, modified to better target a protein (…

This study is testing a new type of cell therapy called CTX112 for people with B-cell blood cancers that have come back or not responded to other treatments. Doctors use CRISPR gene-editing technology to modify donor immune cells to better target and fight the cancer. The main go…

This study is for people who have already been taking the drug pirtobrutinib for chronic lymphocytic leukemia or non-Hodgkin lymphoma in a previous trial. Its main purpose is to monitor the long-term safety of the drug and track how long patients live. It allows participants from…

This study is testing a refined procedure for umbilical cord blood transplants in adults and children with high-risk blood cancers like leukemia and lymphoma. The goal is to see if this optimized approach improves survival and reduces complications compared to standard transplant…

This early-stage study is testing the safety and initial effectiveness of combining two different types of immunotherapy drugs for people with B-cell non-Hodgkin lymphoma that has come back or stopped responding to standard treatments. The trial will enroll about 121 adults who h…

This study is testing a stem cell transplant procedure that does not use radiation to prepare the body. It aims to control Hodgkin and non-Hodgkin lymphoma in patients whose cancer has returned or is hard to treat, including people living with HIV. Researchers will compare how lo…

This early-stage trial is testing the safety and early effectiveness of a new type of CAR T-cell therapy called azer-cel in adults whose B-cell blood cancers have returned or not responded to prior treatments. The therapy uses donor immune cells (allogeneic) engineered to target …

This early study is testing if a drug called Darzalex Faspro can safely lower harmful antibodies in patients with blood cancers. Lowering these antibodies may allow patients who are currently ineligible to receive a potentially life-saving stem cell transplant from a donor. The s…

This early-stage trial is testing the safety and finding the right dose of a new type of CAR-T cell therapy for adults with certain aggressive B-cell lymphomas that have come back or not responded to other treatments, including prior CAR-T therapy. The therapy involves modifying …

This study is testing a new, experimental CAR T-cell therapy called ronde-cel against currently approved CAR T-cell therapies for patients with aggressive large B-cell lymphoma that has returned or not responded to initial chemotherapy. The new therapy is designed to target two m…

This is a first-in-human study testing a new type of personalized immune cell therapy (CAR-T cells) for adults with Non-Hodgkin Lymphoma that has come back or stopped responding to standard treatments. The main goal is to find a safe dose of these modified immune cells, which are…

This study is testing if adding the drug ruxolitinib to the immunotherapy pembrolizumab is safe and can help control several types of lymphoma that have returned or resisted standard chemotherapy. It is for adults with specific T-cell or B-cell lymphomas who have tried at least o…

This study tests a new support program to help young people living with HIV in Zambia get cancer diagnosed earlier and stick with their treatment. It will train peers to offer counseling and education to overcome barriers to care. The goal is to reduce early deaths from cancers l…

This early-stage study is testing a new combination of six different targeted drugs for adults whose B-cell lymphoma has come back or hasn't responded to previous treatment. The main goal is to find the safest dose of this combination and see if it can help control the cancer. Re…

This early-stage study is testing a new, one-time gene therapy called VNX-101 for patients whose B-cell blood cancers have returned or not responded to other treatments. The therapy is designed to help the patient's own immune system continuously fight cancer cells. Researchers w…

This study tracks the long-term safety and survival of people with chronic lymphocytic leukemia or non-Hodgkin lymphoma who have already taken pirtobrutinib in earlier clinical trials. It allows participants from completed Lilly-sponsored studies to continue receiving the drug or…

This is a first-in-human study to find a safe dose of an experimental drug called CC312 for adults with certain B-cell blood cancers that have come back or stopped responding to other therapies. The main goal is to check the drug's safety and how the body processes it in about 44…

This is an early-stage study testing a new type of personalized cell therapy called GB5005 in adults with a specific type of lymphoma (B-cell non-Hodgkin lymphoma) that has come back or not responded to standard treatments. The main goal is to check the safety and side effects of…

This study is testing whether adding a new drug called linperlisib to an existing three-drug combination helps control non-Hodgkin lymphoma that has come back or hasn't responded to previous treatments. It will involve about 180 adults with specific types of lymphoma to see if th…

This program provides access to an experimental drug called AVM0703 for patients with various solid tumors and blood cancers. It is for people who may not have other treatment options. The drug aims to help the body's immune system fight cancer, and early reports show mostly mild…

This study is testing the safety of a new type of stem cell transplant for children whose cancers have come back or are very hard to treat. Doctors use a half-matched family donor and a special process to remove certain immune cells from the transplant, aiming to reduce complicat…

This study is testing a new, experimental cell therapy called LYL314 for adults with aggressive B-cell non-Hodgkin lymphoma that has come back or hasn't responded to other treatments. The therapy, a type of CAR-T, is designed to attack cancer cells by targeting two markers (CD19 …

This early-phase study is testing the safety of an experimental cell therapy called LV009 injection. It is for adults whose CD19-positive blood cancers, like non-Hodgkin lymphoma or acute lymphoblastic leukemia, have returned or not responded to other treatments. The main goal is…

This study is testing a new approach to collecting a patient's own stem cells for a transplant to treat blood cancers like multiple myeloma and lymphoma. The goal is to see if using a standard drug (G-CSF) first and only adding a second drug (Plerixafor) if needed can successfull…

This study is testing whether a combination of three drugs—epcoritamab, zanubrutinib, and rituximab—is safe and effective for people whose follicular or marginal zone lymphoma has come back or hasn't responded to prior treatments. About 45 participants will receive the treatment …

This is an early-stage study testing the safety of a personalized cell therapy for adults with specific types of non-Hodgkin lymphoma that have come back or not responded to standard treatments. Doctors will modify a patient's own immune cells to better target and fight their can…

This early-stage trial is testing a new vaccine designed to prevent serious cytomegalovirus (CMV) infections. The study involves patients with blood cancers who are receiving a stem cell transplant from a partially matched donor, a procedure that carries a high risk of CMV. Resea…

This study is testing whether adding an antibody-boosting medication called Xembify to standard care can help prevent serious bacterial infections in adults with certain blood cancers. Participants must have low antibody levels and a history of severe or frequent infections. The …

This study is testing a new vaccine approach to prevent a common and serious viral infection called CMV in patients receiving a stem cell transplant for blood cancers. Researchers are giving the vaccine to the healthy stem cell donors, hoping the donor's boosted immunity will be …

This study is testing whether a personalized exercise program can help lymphoma and breast cancer patients maintain their physical fitness, heart function, and quality of life during cancer treatment. Researchers will compare two approaches: one group will follow a structured phy…

This study is testing whether following a Mediterranean diet and doing home-based exercise during chemotherapy can help lymphoma patients better complete their treatment and reduce treatment-related side effects. Researchers will enroll 140 adults with lymphoma who are starting c…

This study aims to understand if using cannabis or related products helps people manage symptoms like pain and nausea during cancer treatment. It will follow 2,000 adults newly diagnosed with certain cancers who are starting chemotherapy or immunotherapy. Researchers will track p…

This study aims to understand how children's bodies process a liquid form of the cancer drug venetoclax, which is made by crushing tablets. It involves 30 children and young adults with blood cancers who cannot swallow pills and are already receiving this liquid medicine as part …

This study aims to see if it's practical and acceptable to track how the bodies of children and young adults (ages 6-25) with newly diagnosed Hodgkin or Non-Hodgkin lymphoma process certain test drugs. Participants will take these test drugs at scheduled hospital visits and have …

This study aims to understand how personal relationships and physical activity affect the well-being of young adults who have survived cancer. Researchers will follow 250 young adult survivors for one year, having them complete surveys and wear activity trackers. The goal is to l…

This early-phase study is testing a new type of PET scan that uses a special tracer called 64Cu-GRIP B. The goal is to see if this scan can detect signs of immune cell activity in tumors, which might help doctors predict which patients with hard-to-treat non-Hodgkin lymphoma will…

This study is testing a new artificial intelligence (AI) tool designed to help match people with advanced cancer to suitable clinical trials. It will enroll up to 50,000 patients to see if using this AI system makes it easier for patients to find and join trials. The researchers …

This study aims to discover new genes that cause cancer to run in families, especially those affecting children. Researchers will collect health information, blood, and sometimes leftover tumor samples from families where multiple members have had cancer. The goal is to build a l…

This study aims to understand if exposure to hazardous chemicals during firefighting increases early signs that can lead to blood cancers. Researchers will enroll 300 Charlotte firefighters aged 40-49 with at least 5 years of experience to test their blood for these early markers…

This study is testing a new imaging agent used with PET/CT scans to see if it can better detect and measure certain blood cancers and rare tumors. It involves about 30 adult patients with conditions like non-Hodgkin lymphoma, multiple myeloma, or specific rare diseases. The goal …

This research aims to understand how social factors and genetics affect long-term health in young adults who have survived Hodgkin or Non-Hodgkin lymphoma. The study will follow 2,000 survivors for two years, collecting blood samples and survey data about their quality of life, s…

This study aims to understand and improve communication and support for Spanish-speaking families of children with leukemia or lymphoma. Researchers will interview families to learn about their experiences, needs, and the barriers they face in getting care. The goal is to gather …

This study is a testing service, not a treatment. It aims to analyze tumor samples from patients who received a specific Bristol-Myers Squibb gene therapy for blood cancers and later developed a second, unrelated cancer. The goal is to check if genetic material from the original …